SCHEMBL2354479

SCHEMBL2354479

NC(CO)CO.NC(CO)CO

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
TSHR P16473 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.31
SLC1A1 P43005 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL74076 1.00
Hydrochloric Acid SCHEMBL45666 0.95
Hypochlorous Acid SCHEMBL25425590 0.91
Hydrochloric Acid SCHEMBL31028436 0.91
Cyanide SCHEMBL2693274 0.88
SCHEMBL1504370 0.84
Guanidine SCHEMBL4966645 0.84
SCHEMBL12761607 0.84
SCHEMBL6901463 0.82 ENPEP (0.33) LMNATSHRALDH1A1
SCHEMBL15528706 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104211756-B 2 amino 1,3 propanediol derivative, its preparation, nanostructured, Plumbum removing activity and application 首都医科大学 2017-03-01 CN claimed
CN-104211756-A 2-amino-1,3-propylene glycol derivatives, preparation, nano structure, lead-removing activity, and applications thereof UNIV CAPITAL MEDICAL SCIENCES 2014-12-17 CN claimed
US-20230183620-A1 AGENT CONTAINING EMULSIFIER AND MICROCAPSULES HENKEL AG & CO. KGAA (DE) 2023-06-15 US disclosed
CN-104211756-B 2 amino 1,3 propanediol derivative, its preparation, nanostructured, Plumbum removing activity and application 首都医科大学 2017-03-01 CN disclosed
CN-104211756-A 2-amino-1,3-propylene glycol derivatives, preparation, nano structure, lead-removing activity, and applications thereof UNIV CAPITAL MEDICAL SCIENCES 2014-12-17 CN disclosed
US-20140322156-A1 PROCESS FOR REDUCING MALODOURS HENKEL AG & CO. KGAA (DE) 2014-10-30 US disclosed
US-20110195913-A1 Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer ADOCIA (FR) 2011-08-11 US disclosed
US-7989555-B2 Glycerol derivatives and methods of making same GLOBAL AGRITECH, INC. (US) 2011-08-02 US disclosed
US-7641914-B2 for forming conjugates (liposomes, complexes, nanoparticles) with biologically active substances and releasing them into cellular tissues or acidic compartments, or for use as nonionic surfactant for stabilizing particles encapsulating biodrugs GENCELL, S.A. (FR) 2010-01-05 US disclosed
US-20050222434-A1 Acid-sensitive compounds, their preparation and uses GENCELL S.A. 2005-10-06 US disclosed
US-4221740-A CATALYTIC HYDROGENATION OF THE SODIUM SALT OF 1,3-DIHYDROXY-2-NITROPROPANE SCHERING AKTIENGESELLSCHAFT (DE) 1980-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222434-A1 Acid-sensitive compounds, their preparation and uses LIPA, PHOSPHO1, ACP1 LMNA 2003/4885TSHR 2794/4885ALDH1A1 1301/4885
US-20140322156-A1 PROCESS FOR REDUCING MALODOURS ALDH7A1, ACMSD, MAL2 LMNA 4746/4885TSHR 4414/4885ALDH1A1 69/4885
US-20110195913-A1 Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer CD44, CSGALNACT1, ALG1 LMNA 3186/4885TSHR 1193/4885ALDH1A1 3983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.